Today we are proud to announce our lead investment in Selentus Science, a surgical innovator, to support the development of new surgical haemostat, TenaTac®.
Selentus has developed TenaTac®, an innovative medical device that controls bleeding during a surgical procedure while also reducing the risk of post-operative haemorrhage.
Intra-operative bleeding can extend overall operative and anaesthetic time, potentially increasing both the risks of patient morbidity and mortality, and total healthcare costs. TenaTac® is based on a disruptive new technology that replaces expensive blood products used in current haemostats, eliminating the risk of contamination for patients. It is protected by granted patents in the UK, US, Japan, China and Brazil and is allowed for grant in Europe. It has been approved as a Class III medical device in Europe. TenaTac® is in the process of being commercialised with a European partner.
Selentus is based at Pioneer’s BioCity Nottingham site and the Pioneer investment team have known CEO Ben Nichols for many years, having previously invested in and successfully exited Haemostatix, the company he formerly led. The investment in Selentus is a perfect example of how Pioneer’s early and ongoing involvement with entrepreneurial ventures provides unparalleled insight into the people, the technology and their chances of success.
Pioneer Group operates 10 high tech life sciences campuses in the UK and Ireland alongside nationwide accelerator programmes and partnerships with organisations such as Innovate UK, which together ensure unrivalled access to investment opportunities such as Selentus.
“This investment really validates the innovation at Selentus and will assist in the funding of a post-approval clinical study of our lead device, TenaTac®, and the development of an exciting pipeline of new products for surgical bleeding and wound therapy. We have benefited enormously from working in the BioCity, Nottingham life sciences ecosystem and from Pioneer Group’s specialist and dedicated support network. We intend to continue our ambitious growth plans with Pioneer’s support.”
Ben Nichols, CEO of Selentus
“Our mission is to help life sciences businesses, such as Selentus, thrive at every stage of their innovation journey. We are proud to come in as lead investor in Selentus and strongly believe in the innovation behind TenaTac®, a medical device with an exceptional IP that solves a key gap in the haemostatic market. We are excited to be supporting Selentus’ growth through our investment as well as our all-round incubator programme.”
Dr. Imelda Juniarsih, Investment Manager at Pioneer Group
For more information, please contact:
| Pioneer Group Miranda Knaggs Email: hello@thepioneergroup.com | |
| Pioneer Group – Instinctif Partners (Media) Melanie Toyne-Sewell / Giulia Lasagni / Feyi Ashamu Tel: 0207 457 2020 Email: pioneer@instinctif.com | |
| Selentus Dr. Ben Nichols, CEO Email: bnichols@selentus.com |